The circulating cell-free tumor DNA market plays a vital role as they provide non-invasive options for cancer diagnosis and prognosis. With advantages such as ease of procurement through blood draws and ability to detect cancer across all stages, demand for circulating cell-free tumor DNA is increasing globally. The Global circulating cell-free tumor DNA Market is estimated to be valued at US$ 7.03 Mn in 2024 and is expected to exhibit a CAGR of 6.4% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the circulating cell-free tumor DNA market are BASF SE, Perstorp Holding AB, Chemoxy International Ltd., and Merck Group. BASF SE dominates the market with its comprehensive product portfolio and global presence. Chemoxy International Ltd specializes in research and manufacture of diagnostic kits for non-invasive cancer detection using ccfDNA.
The non-invasive nature of liquid biopsy tests done using circulating cell-free tumor DNA offers major opportunities for market players. It allows for frequent monitoring of disease progression or response to therapy without invasive tissue biopsies. Various industries are also exploring applications of ccfDNA beyond oncology into non-cancer conditions.
North America currently dominates the global circulating cell-free tumor DNA market due to regulatory approvals and favorable reimbursement policies. However, Asia Pacific is anticipated to witness highest growth owing to rising healthcare expenditures and increasing focus on early cancer diagnosis in countries like China and India. Key market players are expanding their presence across Asian and Latin American countries to tap the high growth opportunities.
Market Drivers
Rising incidence of cancer globally is a major Circulating Cell-Free Tumor Dna Market Demand driver as it increases demand for advanced diagnostic methods. According to WHO, cancer burden is expected to rise by ~60% in the next 20 years. Growing awareness about advantages of liquid biopsies compared to traditional tissue biopsies is also driving the ccfDNA market. Continuous technological advancements are enabling detection of various cancer types as well as monitoring of residual diseases or recurrence.
Market Restraints
High capital requirements for setting up research and manufacturing facilities pose a major challenge especially for new market entrants. Stringent regulatory approvals also slow down product launches. Limited clinical validation still remains an issue for insurance coverage and market adoption of some ccfDNA tests. Technological limitations can also restrain detecting rare genetic alterations.
Segment Analysis
The Circulating Cell-Free Tumor DNA market has been segmented by sample type, analysis technology, biomarker type, application, and end-use. The sample type segment includes blood, and others. The blood sample type dominates the market as it is the most widely used sample type for circulating tumor cell-free DNA analysis. It helps in detecting tumor mutations, chromosomal abnormalities, and microsatellite instability in cancer patients.
The analysis technology segment comprises PCR, NGS, microarrays, and others. The NGS segment holds the largest market share due to its ability to analyze cell-free DNA from blood samples in a high-throughput and cost-effective manner. This helps in comprehensive mutational profiling of tumors.
Global Analysis
Regionally, North America dominated the circulating cell-free tumor DNA market in 2019 and is expected to continue its dominance during the forecast period. This is attributed to well-established healthcare infrastructure, rising prevalence of cancer, growing awareness about liquid biopsy, and presence of key players in the region. However, Asia Pacific is anticipated to witness the fastest growth during the forecast period owing to increasing healthcare spending, growing incidence of cancer, focus of key players on emerging Asian countries for business expansion.
Get more insights on Circulating Cell-Free Tumor Dna Market
Also read related article on Cell Cryopreservation Market
Comments
0 comment